Prevalence of Chronic KIdney Disease in Hypertensive Patients

NCT ID: NCT00383968

Last Updated: 2006-10-04

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 248 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2006-10-31
• Study Completion Date: 2006-12-31

Brief Summary

Prevention of progressive renal disease needs a clear understanding of prevalence of early stage of chronic kidney disease in a community. Even in developed countries most subjects in early stages of chronic kidney disease go largely undiagnosed and untreated. Targeted screening could identify a greater numbers of individuals at risk then a general public screening (11). It is economically more feasible to perform in a country like Pakistan. Hypertension and diabetes are highly prevalent in South-Asia.It is anticipated that if target screening of hypertensive population is performed especially of an age group in which intervention might be expected to have maximal benefit it will not only help to identify from a large number of patients with essential hypertension destined to develop or in the course of advancing towards end stage renal disease but will also unearth mislabeled "essential hypertension" that have underlying primary renal disease. This later group may belong to socio-economic disadvantaged population who have limited access to health care and have never been investigated properly. The aim of the Study is to detect sub-clinical chronic kidney disease in hypertensive patients at community level and to identify associated risk factors.

Detailed Description

This will be Cross sectional or prevalent study targeting diagnosed hypertensives aged 40 and above years, in middle to low socio-economic settings of Karachi. This proposed study will be nested in the existing Wellcome Trust funded study. The parent study is designed to determine the impact of a unique community versus high risk approach to control BP in Karachi, Pakistan In that ongoing Factorial design, individuals aged ≥40 who are found hypertensive in the 12 clusters (each containing 250 households) are being randomized to different interventions for their BP control. All participants enrolled in that study had urine examination for proteinuria and serum creatinine measurements at baseline to assess their renal status. For the proposed study the identified hypertensive (from parent study) who had either shown proteinuria and or had elevated serum creatinine (more then 1.2 for females and 1.4 mg/dl for males) at baseline will be approached. Serum creatinine levels exceeding above mentioned cut-off levels, are only reached when GFR is<60ml/min/m². As mentioned above in order to classify these subjects as having chronic kidney disease these abnormalities must be demonstrated to persist for at least three months. A repeat serum creatinine measurement and urine examination for proteinuria will be performed in the present study, by obtaining blood sample and urine sample respectively from these subjects. As a period of three months have already passed since the baseline investigations were done, all subjects who will show persistent abnormalities in either or both test will fall into chronic kidney disease group. The repeated testing to confirm presence of CKD will include, measurement of serum creatinine and urinary albumin/creatinine ratio (>30mg/g) in an untimed urine specimen. This method has been recommended as the preferred screening strategy. A set questionnaire will be filled by interviewing the patient and risk factors for the presence of renal disease will be analyzed based on this information.

The data collection will be done through structured questionnaire and diagnosis will be made on the basis of their persistently elevated kidney biomarkers.

Conditions

Hypertension; Chronic Kidney Disease

Study Design

• Observational Model Type: DEFINED_POPULATION
• Study Time Perspective: OTHER

Eligibility Criteria

Inclusion Criteria

• Known hypertensives aged 40 and above with microalbuminuria and/or elevated serum creatinine on first evaluation.
• Hypertension: Systolic blood pressure ≥140, and /or diastolic blood pressure ≥ 90 with or without antihypertensive drugs.
• Microalbuminuria:

• Albumin concentration of 20-200mg/L, with albumin-to-creatinine ratio of 3-30mg/mmol or 30-300mg/g
• Female: 3.0-30.0mg/mmol or 30-300mg/g
• Male: 2.0-20.0mg/mmol or 20
• Elevated Serum creatinine:

• Female: >1.2mg/dl
• Male: >1.4mg/dl

Exclusion Criteria

• Known diabetics will be excluded.
• unable to give informed consent

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Aga Khan University

OTHER

Sponsor Role: lead

Principal Investigators

Tazeen H Jafar, MD, MPH

Role: STUDY_DIRECTOR

Aga Khan University

Muslima A Ejaz, MBBS

Role: PRINCIPAL_INVESTIGATOR

Aga Khan University

Locations

Aga Khan University

Karachi, Sindh, Pakistan

Site Status: RECRUITING

Countries

Pakistan

Central Contacts

Muslima Ejaz A Ejaz, MBBS

Role: CONTACT

Phone: 4864860

Email: muslima.ejaz@aku.edu

Tazeen H Jafar, MD,MPH

Role: CONTACT

Phone: 4930051

Email: tazeen.jafar@aku.edu

Facility Contacts

Muslima A Ejaz, MBBS

Role: primary

Tazeen H Jafar, MD, MPH

Role: backup

Other Identifiers

06GS009CHS

Identifier Type: -

Identifier Source: org_study_id